RVMD
The table below shows Revolution Medicines, Inc.'s cash flow statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$897.74M | -$557.44M | -$350.57M | -$224.40M | -$147.18M | -$100.06M |
| Capital expenditure | $15.99M | $10.31M | $7.73M | $10.82M | $6.53M | $2.93M |
| Investing cash flow | $118.06M | -$554.39M | -$342.60M | -$24.12M | -$142.12M | -$234.23M |
| Dividends paid | - | - | - | - |
Revolution Medicines, Inc. reported operating cash flow of -$897.74M for fiscal year 2025. That is down 61.0% from -$557.44M in fiscal 2024. Over the 8 fiscal years shown, operating cash flow declined from $1.21M (FY 2018) to -$897.74M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| $0.00 |
| Stock buybacks | - | - | - | - | - | - |
| Financing cash flow | $621.52M | $959.41M | $1.23B | $301.43M | $294.18M | $422.78M |